期刊文献+

氯沙坦与吲达帕胺联合钙离子拮抗剂治疗3级高血压伴左室肥厚的临床对照研究 被引量:1

下载PDF
导出
摘要 目的:探讨氯沙坦与吲达帕胺联合钙离子拮抗剂治疗3级高血压伴左室肥厚的临床疗效及对血钾、肾功能的影响。方法:选择本院收治的3级高血压伴左室肥厚患者为研究对象,根据随机数字表法分为氯沙坦组和吲达帕胺组,对比分析治疗8周后两组患者的血压控制情况、超声心动图表现、血钾及肾功能情况。结果:治疗8周后,两组显效率及总有效率比较差异均无统计学意义(P>0.05)。氯沙坦组治疗后LVDd、LVST、PWT、LVM及LVMI均较治疗前明显改善(P<0.01),吲达帕胺组LVST、PWT、LVM及LVMI也均较治疗前明显改善,但LVDd改善不明显,且氯沙坦组各指标改善更为明显(P<0.05)。氯沙坦组血UA较治疗前明显降低(P<0.01),Scr略有降低,血钾略有升高,但差异均无统计学意义(P>0.05)。吲达帕胺组血UA较治疗前明显升高,血钾明显降低(P<0.01),Scr较治疗前略有升高,但差异无统计学意义(P>0.05)。氯沙坦组eGFR平均值明显高于吲达帕胺组,且肾功能损害发生率明显低于吲达帕胺组(P<0.05)。另外,氯沙坦组在用药过程中未发现明显不良反应,吲达帕胺组有37.8%的患者出现低血钾,明显高于氯沙坦组(P<0.01)。结论:氯沙坦联合钙离子拮抗剂治疗3级高血压伴左室肥厚,不仅具有良好的降压效果,而且能更好地起到缓解左室肥厚和保护肾脏的作用,同时能有效避免或降低不良事件的发生,值得临床推广。
作者 李新玲
出处 《中国医学创新》 CAS 2014年第5期73-75,共3页 Medical Innovation of China
  • 相关文献

参考文献9

  • 1Okin P M, Devereux R B, Jern S, et al.Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events[J].JAMA, 2004, 292 ( 19 ) : 2343-2349.
  • 2Devereux R B, Pickering T G, Harshfield G A, et al.Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress[J].Circulation, 1983, 68 ( 3 ) : 470-476.
  • 3杜晓军,李雷.吲哒帕胺治疗老年高血压临床观察[J].中国校医,2006,20(4):426-427. 被引量:4
  • 4郭冀珍,孙宁玲,吴宗贵,黄高忠.动态血压监测评价吲哒帕胺新型缓释片的降压作用[J].中华心血管病杂志,2002,30(7):393-396. 被引量:13
  • 5Johnson R J, Kang D H, Feig D, et al.Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?[J]. Hypertension, 2003, 41 (6): 1183-1190.
  • 6何森,陈晓平,蒋凌云,彭勇,龚玲,陈小妮,吴凯,崔凯军,祝烨,黄德嘉.中老年人群血尿酸水平和早期肾功能损害的关系[J].中华医学杂志,2010,90(10):658-661. 被引量:24
  • 7Lonn E, Shaikholeslami R, Yi Q, et al.Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation ( HOPE ) Trial[J].J Am Coll Cardiol, 2004, 43 ( 12 ) : 2200-2206.
  • 8Mattioli A V, Bonatti S, Monopoli D, et al.Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension[J].Blood Press, 2005, 14 ( 5 ) : 273- 278.
  • 9于海波,韩雅玲,高柏青,佟铭,张新娅,王祖禄,许凤芝.替米沙坦改善原发性高血压病患者心肌肥厚及早期肾功能失调[J].心脏杂志,2005,17(1):39-41. 被引量:8

二级参考文献24

  • 1方志高.替米沙坦治疗充血性心力衰竭的临床观察[J].心脏杂志,2004,16(4):342-343. 被引量:5
  • 2全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估[J].中华肾脏病杂志,2006,22(10):589-595. 被引量:710
  • 3Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? aprospective cohort study of Japanese male workers. J Epidemiol,2000 ,10 :4403-4409.
  • 4Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemias a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis ,2004,44:642-650.
  • 5Levey AS, Coresh J, Balk E, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med, 2003,139:137- 147.
  • 6Johnson R J, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension, 2003, 41 : 1183-1190.
  • 7Amato D, Cleto AA, Rutila CL, et al. Prevalence of chronic kidney disease in an urban Mexican population. Kidney Int, 2005, 68:11-17.
  • 8Siu YP, Leung T,Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis, 2006,47:51-59.
  • 9Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man .automatic validation of the method[J]. Circulation, 1977, 55:613-618.
  • 10Michel MC, Bohner H, Koster J, et al. Safety of telmisartan in patients with arterial hypertension : an open-label observational study[J]. Drug Saf, 2004, 27(5):335-344.

共引文献44

同被引文献14

  • 1张维忠.新型钙拮抗剂贝尼地平基础与临床研究进展[J].高血压杂志,2005,13(4):196-197. 被引量:33
  • 2Tamsma J T,Jazet I M,Beishuizen E D,et al.The metabolic syndrome:a vascular perspective[J].Eur J Intern Med,2005,16(5):314-320.
  • 3Brener B M,Cooper M E,De Zeeuw D,et al.Effects of losartanon renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J].N Engl J Med,2001,345(12):861-869.
  • 4Sever P S,Dahlof B,Poulter N R,et al.Prevention of coronary and stroke events with atrovastation in hypertensive patients who have average or lower-than-average cholesterol concentrations,in the Anglo-scandinavian cardiac outcomes trial-lipid lowering arm(ASCOT-LLA):a milticentre randomised controlled trial[J].Lancet,2003,361(9364):1149-1158.
  • 5The ALLHAT Officer and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in moderately hypercholesterolemic,hypertensive patients randomized to pravastatin vs usual care.The antihypertensive and lipid-lowering treatment to prevent heart attack trial(ALLHAT-LLT)[J].JAMA,2002,288(23):2998-3007.
  • 6Yamada H,Suga N,Maeda K,et al.Effects of combination therapy with angiotensinⅡtype 1 receptor blockers and calcium channel blookers on renal function in hypertensive patients/a retrospective“real-world”comparative study[J].Arzneimittelforschung,2010,60(2):64-70.
  • 7Hayashi K,Wakino S,Sugano N,et al.Ca2+channel subtypes and pharmacolgy in the kidney[J].Circ Res,2007,100(3):342-353.
  • 8Wang Y,Kimura S,Fujisama Y,et al.Benidipine dilates both pre and post glomemlar arteriole in the canine kidney[J].Hyper tens Res,2001,24(4):429-436.
  • 9谌贻璞.不同种类双氢吡啶钙通道阻滞剂的肾脏保护作用[J].北京医学,2009,31(3):178-180. 被引量:3
  • 10谢爽,张沛,贾友宏,胡大一,何青,吴宗贵,陈君柱,黎莉,李树仁,王海昌,王燕妮,魏盟,李一石.盐酸贝尼地平治疗稳定型心绞痛的多中心临床研究[J].中国药学杂志,2010,45(9):682-685. 被引量:9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部